A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

This study is comparing two treatment strategies for Stage III non-small cell lung cancer (NSCLC) that may be surgically removable: one group receives chemoimmunotherapy before and after surgery, while the other receives chemoradiotherapy followed by immunotherapy. The goal is to see which approach leads to better outcomes. **You may be eligible if...** - You are between 18 and 75 years old - You have Stage IIIA or IIIB NSCLC confirmed by biopsy - Your cancer is deemed potentially removable by a multidisciplinary team - You have not had any prior cancer treatment for lung cancer - Your lung function is adequate (FEV1 and DLCO ≥ 50% predicted) - You have no EGFR or ALK mutations (if adenocarcinoma) **You may NOT be eligible if...** - You have had surgery, chemotherapy, radiation, or immunotherapy for lung cancer before - You have had another type of cancer previously - Your heart or lung function is significantly impaired - Your cancer is not potentially resectable after review Talk to your doctor to see if this trial is right for you.